Suggested remit - To appraise the clinical and cost effectiveness of ERC1671 within its marketing authorisation for treating glioblastoma in adults with disease that has progressed or recurred following treatment with radiotherapy and temozolomide
The company has been unable to source all the necessary evidence to provide a submission that meets the requirements of the scope for this appraisal within the required timelines. Therefore the company and NICE have agreed to put the appraisal on hold. Consequently the discussion of this appraisal at the committee meeting scheduled on 14 July 2020 will not take place. We will update you on our progress and next steps for this appraisal as soon as possible.
- Status:
- Suspended
- Decision:
- Selected
- Process:
- TA
- ID number:
- 1623
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- ERC - Epitopoietic Research Corporation
- Patient carer groups
- The Brain Tumour Charity
- Braintrust
- Professional groups
- Association of British Neurologists
- Cancer Research
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- General commentators
- All Wales Therapeutics & Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 May 2020 | Suspended. The company has been unable to source all the necessary evidence to provide a submission that meets the requirements of the scope for this appraisal within the required timelines. Therefore the company and NICE have agreed to put the appraisal on hold. Consequently the discussion of this appraisal at the committee meeting scheduled on 14 July 2020 will not take place. We will update you on our progress and next steps for this appraisal as soon as possible. |
| 11 November 2019 | Invitation to participate |
| 14 October 2019 (10:00) | Scoping workshop (Manchester) |
| 19 August 2019 - 17 September 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 10 May 2019 | In progress. Referred 29 April 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual